Circulating human leucocyte elastase in patients with inflammatory bowel disease

E O ADEYEMI, S NEUMANN, V S CHADWICK, H J F HODGSON, AND M B PEPPYS

From the Gastroenterology Unit, and the MRC Acute Phase Protein Research Group, Immunological Medicine Unit, Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, and E Merck, D-6100 Darmstadt-I, Federal Republic of Germany

SUMMARY  The plasma concentration of human leucocyte elastase (HLE), measured by enzyme immunoassay as the complex with \( \alpha_1 \)-proteinase inhibitor, was determined in 94 patients with active and inactive inflammatory bowel disease. In Crohn’s disease and in ulcerative colitis human leucocyte elastase levels were raised significantly above normal when the disease was active, and fell on remission. The mean human leucocyte elastase level in 31 cases of active Crohn’s disease was significantly greater than the mean human leucocyte elastase level in 23 patients with active ulcerative colitis (\( p=0.013 \)). The values of human leucocyte elastase correlated significantly with Crohn’s disease activity index scores (\( p=0.05 \)) and with the circulating concentration of C-reactive protein (\( p<0.05 \) and \( p<0.01 \) for ulcerative colitis and Crohn’s disease respectively), but not with the erythrocyte sedimentation rate. These results indicate that the concentration of human leucocyte elastase in the plasma of patients with inflammatory bowel disease reflects the activity of their intestinal disease and suggest that serial measurements of human leucocyte elastase may be useful in the assessment and clinical management of these conditions.

Human leucocyte elastase (HLE), a neutral proteinase normally stored in the azurophil granules of the polymorphonuclear leucocytes, is released into the extracellular space during the process of phagocytosis. At physiological pH, it cleaves many structural and soluble proteins including the components of the complement system.\(^1\) It may thus be an important mediator of inflammation and tissue damage, and increased plasma levels of human leucocyte elastase have been reported in septicaemia,\(^5\)\(^6\) where they correlated with clinical status,\(^6\) in leukaemia\(^5\)\(^6\) and in rheumatoid arthritis.\(^7\)

Neutrophil infiltration is a constant histological finding in the lesions of ulcerative colitis and is frequently seen in Crohn’s disease, suggesting that elastase may participate in the pathogenesis of these diseases. We report here that plasma concentrations of human leucocyte elastase measured by a new solid phase enzyme immunoassay technique\(^8\) are raised in patients with active inflammatory bowel disease and suggest that the circulating concentration of human leucocyte elastase may be used as a marker of disease activity.

Methods

PATIENTS  Fifty six individuals with Crohn’s disease and 38 with ulcerative colitis who were all under the care of the Gastroenterology Unit, Department of Medicine, Hammersmith Hospital, were studied between November 1982 and March 1984 (Table). The diagnoses were based on standard clinical, radiological and histopathological features, the latter according to the criteria of Lockhart-Mummery and Morson.\(^9\)\(^11\)

CONTROLS  Healthy volunteer blood donors (180 individuals) and 20 healthy adult hospital workers were used as controls to establish the normal range of human leucocyte elastase concentration in plasma.
Circulating human leucocyte elastase in patients with inflammatory bowel disease

Table  Patients studied

<table>
<thead>
<tr>
<th></th>
<th>Normal controls</th>
<th>Crohn's disease</th>
<th>Ulcerative colitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>200</td>
<td>56</td>
<td>38</td>
</tr>
<tr>
<td>Age range (mean)</td>
<td>18–36 (34)</td>
<td>17–83 (43-2)</td>
<td>17–78 (45-2)</td>
</tr>
<tr>
<td>Sex ratio (M:F)</td>
<td>1:5:1</td>
<td>1:1.5</td>
<td>2:1</td>
</tr>
<tr>
<td>Ethnic origin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>200</td>
<td>49</td>
<td>33</td>
</tr>
<tr>
<td>Asian</td>
<td>—</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>West Indian</td>
<td>—</td>
<td>4</td>
<td>—</td>
</tr>
</tbody>
</table>

INVESTIGATIONS
At the same time at which blood was taken for assay of human leucocyte elastase and other variables, the level of disease activity was assessed clinically according to the criteria of de Dombal et al. for Crohn’s disease and Truelove and Witts for ulcerative colitis. On the basis of this assessment the disease in each case was classified as being active or inactive. In addition the Crohn’s disease activity index (CDAI) was calculated for inpatients with Crohn’s disease.

For determination of the circulating concentration of human leucocyte elastase, venous blood was drawn into EDTA and kept at 4°C until the plasma was separated by centrifugation at 1000 g for 10 minutes at 4°C. Separation was usually done within one hour of venesection and never more than three hours afterwards. The upper third of the plasma was carefully aspirated and was then stored in aliquots at −20°C before assay. Because the circulating neutrophils are obviously an extremely rich source of elastase, great care in handling and separating the plasma, as described above, is essential to avoid artefactual in vitro release of the enzyme. Extensive preliminary tests on over 200 samples from patients with different diseases, including inflammatory bowel disease, established that with the present procedure, there was no correlation between plasma human leucocyte elastase and the circulating total leucocyte or neutrophil counts. The human leucocyte elastase concentration was determined by a commercial solid phase enzyme immunoassay, carried out precisely according to the manufacturer’s instructions (E Merck, D-6100 Darmstadt-1, FRG; available from EM Diagnostics Ltd, Greenford, Middlesex UB6 8PN). The method depends on uptake of the elastase-α1-proteinase inhibitor complex, the form in which human leucocyte elastase circulates in the plasma, by immobilised anti-elastase antibodies and their detection by enzyme-labelled anti-α1-proteinase inhibitor antibodies. Inter and intra-assay coefficients of variation were 10% or less and the lower limit of sensitivity of the assay was 13 μg/l.

The concentration of C-reactive protein (CRP), the classical acute phase reactant, the serum concentrations and behaviour of which have been extensively documented in inflammatory bowel disease, was also measured in the same plasma samples. The technique of electroimmunoassay (lower limit of sensitivity 2 mg/l) was used precisely as previously reported and no difference was detected between results obtained with EDTA-plasma and with serum derived from the same blood samples in 30 different subjects. Among normal subjects 90% have CRP values less than 3 mg/l and 99% are less than 10 mg/l. The erythrocyte sedimentation rate (ESR) was measured by the Westergren method in portions of the same samples used for C-reactive protein and human leucocyte elastase assays.

STATISTICAL METHODS
Differences between the mean human leucocyte elastase concentrations in different disease groups were sought by unpaired Student’s t-tests and in serial studies by paired t-tests. As C-reactive protein values cover an extended dynamic range and are generally not normally distributed, differences between groups were sought by non-parametric tests, the Wilcoxon’s rank sum test and the Mann-Whitney U-test. Correlation between different variables was sought using Spearman’s rank correlation coefficient.

Results
PLASMA HUMAN LEUCOCYTE ELASTASE CONCENTRATION IN INFLAMMATORY BOWEL DISEASE
The human leucocyte elastase concentrations in healthy normal controls showed a near normal distribution with a mean of 55 μg/l and a standard deviation of 14 (Fig. 1). The normal range (2 SD about the mean) was thus established to be 27–83 μg/l. Patients with active Crohn’s disease and ulcerative colitis had raised human leucocyte elastase concentrations. The mean concentration in 31 cases of active Crohn’s disease was 169 μg/l, while in 23 patients with active ulcerative colitis it was 119 μg/l. These values were both highly significantly different from normal (p<0.0001). In addition the mean human leucocyte elastase in patients with active Crohn’s disease was higher than in patients with active ulcerative colitis (p=0.013). Among patients with active Crohn’s disease, 13 had predominantly small bowel disease, 14 large bowel and only four had combined small and large bowel Crohn’s disease. The mean human leucocyte
elastase values in these subgroups were 158, 166, and 213 µg/l respectively and were not significantly different from each other.

Twenty five patients with inactive Crohn's disease and 15 patients with quiescent ulcerative colitis had mean human leucocyte elastase concentrations of 69 and 74 µg/l respectively (Fig. 1). These values were significantly less than those seen in active Crohn's disease and ulcerative colitis (p=0.0001 and p=0.0014 respectively), but did not differ from each other. They were, however, both greater than normal (p<0.01).

In 25 patients with active Crohn's disease repeat measurements of plasma human leucocyte elastase concentration were available after treatment when the disease was quiescent. There was a significant fall from a mean of 174 µg/l to 80 µg/l (p<0.00001) (Fig. 2). In 15 patients with ulcerative colitis who were tested when active and in remission the mean human leucocyte elastase value fell from 132 µg/l to 77 µg/l (p=0.00009) (Fig. 3).

**Comparison of Plasma Human Leucocyte Elastase Concentrations with Other Laboratory Measurements**

As previously reported the circulating C-reactive protein concentration was raised in active...
Circulating human leucocyte elastase in patients with inflammatory bowel disease

inflammatory bowel disease, being greater in Crohn’s disease (median 20 mg/l, range <2–237 mg/l, n=31) than in ulcerative colitis (median 6 mg/l, range <2–110, n=23) (p=0·019). In both groups of patients there was a significant correlation between human leucocyte elastase and C-reactive protein values: Crohn’s disease, R=0·57, p<0·01 (Fig. 4) and ulcerative colitis, R=0·37, p<0·05 (Fig. 5). In inactive Crohn’s disease the median plasma CRP value was 3 mg/l and in inactive ulcerative colitis it was <2 mg/l.

The CDAI was calculated for 19 patients and it correlated significantly with their human leucocyte elastase concentrations (R=0·481, p<0·005) (Fig. 6).

Erythrocyte sedimentation rate values were greater than normal in both groups of patients and also in patients with inactive disease. They did not correlate significantly with plasma human leucocyte elastase concentrations.

Discussion

Although the pathogenesis of inflammatory bowel disease is not understood, the presence of neutrophil polymorphonuclear leucocytes in the lesions and their known capacity for production of tissue injury makes them important candidates as mediators of inflammation and organ damage. Indeed there is an excellent correlation between clinical and objective assessments of disease activity in Crohn’s disease and the number of autologous granulocytes excreted in the faeces.19

Information about elastase, exocytosed by neut-
Adeyemi, Neumann, Chadwick, Hodgson, and Pepys

Elastase has previously been studied in the lesions of inflammatory bowel disease. The failure of Kane and Vincent, however, to detect any difference in the elastase content of the rectal biopsies from patients with active or inactive inflammatory and functional bowel disorders probably reflects the fact that they were using an assay for specific protease activity. Such activity is normally extremely short lived in vivo as a result of rapid formation of HLE-α1-proteinase inhibitor complexes. The inhibitor is of relatively low molecular weight and rapidly attains inhibitory concentrations in inflammatory exudates. In the present study human leucocyte elastase was detected and assayed immunochromatically as the physiological enzymatically inactive proteinase-inhibitor complex and the finding of raised plasma concentrations is in agreement with the observations both by Kane and Vincent and by O'Morain et al of increased concentrations of other neutrophil markers in the lesions. Investigation of the presence of HLE-α1-proteinase inhibitor complexes in the faeces of patients with inflammatory bowel disease will be of interest, and may provide additional evidence of pathogenetic importance, but such studies have yet to be undertaken.

Differences between Crohn's disease and ulcerative colitis in the concentration of several serum markers have been reported. Although the early claim by Falchuk et al that serum lysozyme concentrations were higher in Crohn's disease than in ulcerative colitis and could be used for differential diagnosis, was not supported by subsequent studies, there is a general trend towards higher values in Crohn's disease. Similarly the serum concentration of C-reactive protein is usually greater in patients with Crohn's disease than in those with ulcerative colitis for any given degree of disease activity and perhaps as a consequence of the extended dynamic range of C-reactive protein, this difference attains a high degree of statistical significance. The present findings with plasma human leucocyte elastase concentrations follow a similar, albeit less marked pattern but in view of the overlap between the two conditions, human leucocyte elastase measurements clearly do not convey any useful differential diagnostic information in individual cases.

As with other clinical laboratory correlative studies in inflammatory bowel disease there are some exceptional patients in whom human leucocyte elastase is raised in the absence of symptoms and others with clinical activity but no or only a minor rise of the human leucocyte elastase value. The false negative result may arise when symptoms are largely caused by, for example, fixed fibrous obstruction rather than by inflammation, while corticosteroid therapy may, in contrast, increase feelings of well being and mask symptoms without suppressing inflammatory activity. Rather than limiting the usefulness of human leucocyte elastase assays, findings of this type suggest that knowledge of the human leucocyte elastase concentrations should be a valuable component of the assessment of disease activity in inflammatory bowel disease and in monitoring its response to therapy. Further detailed and serial studies are clearly indicated to investigate this prospect.

We are indebted to Dr T Davis and colleagues of the National Blood Transfusion Centre, Edgware, Middlesex, for the normal control specimens. This study was supported in part by MRC Programme Grant G979/51 to MBP and by E Merck, Darmstadt, FRG.

References

Circulating human leucocyte elastase in patients with inflammatory bowel disease


Circulating human leucocyte elastase in patients with inflammatory bowel disease.

E O Adeyemi, S Neumann, V S Chadwick, H J Hodgson and M B Pepys

*Gut* 1985 26: 1306-1311
doi: 10.1136/gut.26.12.1306